前立腺がん、遺伝的リスク、および公平なスクリーニング研究 (ProGRESS) (ProGRESS)
前立腺がん、遺伝的リスク、および公平なスクリーニング研究 (ProGRESS): 前立腺がんの精密スクリーニングの実用的試験
Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, new genetic testing might help identify which men are at highest risk for prostate cancer. This study will examine whether a genetic test helps identify men at risk for significant prostate cancer while helping men who are at low risk for prostate cancer avoid unnecessary biopsies. If this genetic test proves beneficial, it will improve the way that healthcare providers screen male Veterans for prostate cancer.
調査の概要
詳細な説明
Prostate cancer is the most common non-cutaneous cancer in US men and in the Veterans Health Administration (VHA): 1 in 8 will be diagnosed with the disease in their lifetime. Many cases are non-lethal, but prostate cancer remains the 2nd leading cause of cancer death among US men, representing 2.5% of all deaths. VHA diagnoses >16,000 new cases annually and cares for >400,000 men living with prostate cancer. As a result, prostate cancer diagnosis and treatment is a national priority for VHA.
A major impediment to reducing the incidence of metastatic prostate cancer and prostate cancer death is the lack of an optimal screening strategy to identify men at high risk. Screening with prostate-specific antigen (PSA) testing modestly reduces prostate cancer deaths but at the cost of overdiagnoses and overtreatment. Current screening approaches do not adequately distinguish men without prostate cancer or with low-grade prostate cancer amenable to active surveillance from men with clinically significant prostate cancer, who need treatment. As a result, clinical guidelines do not recommend universal prostate cancer screening, including those from the United States Preventive Services Task Force (USPSTF) and the VHA National Center for Health Promotion and Disease Prevention. Still, many men undergo screening based on variable and subjective assessments of their race/ethnicity, family history, and other risk factors.
A new paradigm of precision screening could improve the benefit-to-harm ratio of screening by implementing screening strategies tailored to an individual's specific genetic profile. Due to advances in high-throughput genotyping and sequencing, increasingly large and diverse cohort studies, and standardization of genetic variant classification, germline genetic testing is emerging as a powerful predictor for prostate cancer, including metastatic and lethal disease. This includes both rare highly penetrant variants and polygenic risk scores (PRS), which characterize an individual's predisposition to prostate cancer due to common genetic variation. Rare and common genetic variation is now an equally powerful predictor of clinically significant disease as self-reported race or family history, including in the Million Veteran Program.
This clinical trial will evaluate the promise of precision risk stratification to identify men most likely to benefit from prostate cancer screening. During the proof-of-concept phase, the investigators will achieve the following aims:
- Develop a precision prostate cancer screening intervention consisting of genetic testing for rare variants and a transancestry PRS, delivered to participants and their primary care providers along with individualized, genetic risk-informed screening recommendations.
- Determine the feasibility of enrolling men aged 55-70 ( 35% of whom are of racial/ethnic minority groups) to a pragmatic randomized clinical trial (RCT) comparing the precision screening intervention to usual care.
- Perform an interim assessment to determine whether the observed trajectory of negative prostate biopsy event rates is consistent with rates needed to detect a meaningful between-group difference at the end of the 7-year project period.
Following demonstration of enrollment feasibility and observation of adequate event rates during the proof-of-concept phase, the RCT will continue to the clinical trial phase to test the following co-primary hypotheses:
- Compared with men in the usual care arm, men in the precision screening arm will have a higher incidence rate of clinically significant prostate cancer (csPCa, defined as NCCN classification intermediate risk or higher) detection over the trial follow-up period.
- Compared with men in the usual care arm, men in the precision screening arm will have a lower incidence rate of negative prostate biopsies over the trial follow-up period.
Pre-specified subgroup analyses will test these hypotheses in Black men specifically, to evaluate whether this population benefits equally or more from the intervention. Enrollees will be followed for additional outcomes including all prostate cancer diagnoses, PSA testing, prostate MRI, rare variants identified, preferences for or against prostate cancer screening, and health-related quality of life.
The investigators expect that precision screening will increase screening among high-risk patients but decrease screening among low- and average-risk patients, thereby maintaining or improving overall csPCa detection while improving the population-level benefit-to-harm ratio. Rigorous RCT evidence that genetic risk-informed screening maintains the benefits of screening while minimizing the harms of unnecessary procedures and treatments among low-risk men will change clinical practice and policy around prostate cancer screening.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Charles A Brunette, PhD
- 電話番号:(857) 364-6324
- メール:charles.brunette@va.gov
研究場所
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02130-4817
- 募集
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
-
コンタクト:
- Charles A Brunette, PhD
- 電話番号:(857) 364-6324
- メール:charles.brunette@va.gov
-
主任研究者:
- Jason L Vassy, MD MPH
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- baseline age 55-69 years
- receipt of regular VA care
- Veteran status
Exclusion Criteria:
- personal history of prostate cancer
- prior prostate biopsy, prostatectomy, or prostate MRI
- known carrier status of rare variant associated with cancer syndrome
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ふるい分け
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Precision screening intervention
The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening. |
The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening. |
|
実験的:Usual care
Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening. |
Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Diagnosis of clinically significant prostate cancer
時間枠:7 years
|
Cases of csPCa will be abstracted from VA and survey data and defined using NCCN classifications of intermediate risk or higher: PSA 10 and/or Grade Group 2 and/or clinical T stage T2b |
7 years
|
|
Negative prostate biopsy
時間枠:7 years
|
Counts of negative prostate biopsies not temporally associated with csPCa (within 6 months of diagnosis) will be abstracted from VA and survey data |
7 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Diagnosis of prostate cancer
時間枠:7 years
|
All cases of prostate cancer will be abstracted from VA and survey data |
7 years
|
|
Prostate biopsy
時間枠:7 years
|
Counts of all prostate biopsies will be abstracted from VA and survey data. |
7 years
|
|
PSA testing
時間枠:7 years
|
PSA testing will be identified from VA and survey data |
7 years
|
|
Prostate MRI
時間枠:7 years
|
Prostate magnetic resonance imaging will be identified from VA and survey data |
7 years
|
|
Self-rated health
時間枠:7 years
|
Self-rated health will be collected at the baseline survey and every 6 months with a single-item self-rating of health on a Likert scale from "poor" to "excellent. |
7 years
|
|
Quality of life
時間枠:5 years
|
Health-related quality of life is collected through the Veterans RAND 12-Item Health Survey (VR-12) on the baseline survey and at each participant's 5-year survey or last survey |
5 years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Adherence to precision cancer screening recommendations
時間枠:7 years
|
The precision screening intervention will include the recommendation that high-risk men undergo PSA screening and that low-risk men not undergo screening. The investigators will define adherence to the intervention in these two groups of men as the presence and absence of PSA testing, respectively, during the observation period. |
7 years
|
|
Acceptability of the precision prostate cancer screening intervention
時間枠:7 years
|
The survey will assess patient acceptability of the precision screening with a 3-item instrument assessing patient perspective on the 1) amount of information presented, 2) length of the information, 3) clarity of the information, with each domain scored on a 5-point Likert scale. |
7 years
|
|
Rare pathogenic/likely pathogenic variants
時間枠:7 years
|
Proportion of participants with a rare P/LP variant associated with hereditary prostate cancer |
7 years
|
協力者と研究者
捜査官
- 主任研究者:Jason L Vassy, MD MPH、VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
出版物と役立つリンク
一般刊行物
- Griffin JN, Danowski ME, Gerety HL, Lafferty K, Clayman ML, Antwi AA, Bertero MG, Brunette CA, Gillespie C, Guentert L, Lennon NJ, Martin J, Patel LS, Vassy JL. Development and pilot testing of a prostate cancer polygenic risk report. BMC Med Genomics. 2026 Jul 30;19(1):137. doi: 10.1186/s12920-026-02416-4.
- Vassy JL, Dornisch AM, Karunamuni R, Gatzen M, Kachulis CJ, Lennon NJ, Brunette CA, Danowski ME, Hauger RL, Garraway IP, Kibel AS, Lee KM, Lynch JA, Maxwell KN, Ratner D, Rose BS, Teerlink CC, Xu GJ, Hofherr SE, Lafferty KA, Larkin K, Malolepsza E, Patterson CJ, Toledo DM, Donovan JL, Hamdy FC, Martin RM, Neal DE, Turner EL, Andreassen OA, Dale AM, Mills IG, Abraham A, Batra J, Clements J, Cussenot O, Cybulski C, Eeles RA, Fowke JH, Grindedal EM, Gronberg H, Hamilton RJ, Lim J, Lu YJ, MacInnis RJ, Maier C, Mucci LA, Multigner L, Neuhausen SL, Nielsen SF, Parent ME, Park JY, Petrovics G, Plym A, Razack A, Rosenstein BS, Schleutker J, Sorensen KD, Townsend PA, Travis RC, Vega A, West CML, Wiklund F, Zheng W; Profile Steering Committee; IMPACT Study Steering Committee and Collaborators; PRACTICAL Consortium; VA Million Veteran Program; Seibert TM. Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study. Nat Cancer. 2026 Feb;7(2):352-367. doi: 10.1038/s43018-025-01103-0. Epub 2026 Jan 26.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- ONCA-021-22F
- I01CX002635 (米国 NIH グラント/契約)
- 5I01HX003541-02 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data will be stored in a data repository available for request by approved individuals.
IPD 共有アクセス基準
Requestors may be required to have IRB approval, data use agreements, and other regulatory and administrative credentials and authorizations prior to receiving data.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。